Pervasis Therapeutics names new president and CEO

Mr Chereau was formerly the vice president and general manager of Genzyme Cardiovascular, a business unit within Genzyme in Cambridge. Mr Chereau also led Genzyme’s cardiovascular business development activities, including, most recently its in-licensing transaction with Isis Pharmaceuticals.

Stephen Bollinger, COO of Pervasis Therapeutics, said: “Fred’s addition to Pervasis truly rounds out the stellar management team the company has assembled. Under Fred’s leadership, we will continue to develop the company and bring our biologically active therapeutics to a large number of patients.”